Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to Hold at StockNews.com

StockNews.com downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a hold rating in a research report sent to investors on Sunday.

A number of other research analysts have also commented on the company. HC Wainwright reaffirmed a buy rating and set a $395.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday, March 5th. BMO Capital Markets reissued an outperform rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 27th. Royal Bank of Canada reissued an outperform rating and issued a $235.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. JPMorgan Chase & Co. increased their target price on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a neutral rating in a research report on Thursday, February 1st. Finally, Wells Fargo & Company decreased their target price on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an equal weight rating for the company in a research report on Friday, February 16th. Nine equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $216.12.

Alnylam Pharmaceuticals Stock Up 0.2 %

Alnylam Pharmaceuticals stock opened at $146.07 on Friday. The business has a 50-day simple moving average of $151.09 and a 200 day simple moving average of $166.50. Alnylam Pharmaceuticals has a 52 week low of $143.50 and a 52 week high of $218.88. The stock has a market cap of $18.40 billion, a price-to-earnings ratio of -41.03 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to analysts’ expectations of $439.38 million. The company’s revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.68) earnings per share. On average, research analysts anticipate that Alnylam Pharmaceuticals will post -4.54 earnings per share for the current year.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. Harbor Capital Advisors Inc. lifted its stake in Alnylam Pharmaceuticals by 1.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 51 shares in the last quarter. EP Wealth Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 6.4% during the 3rd quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 71 shares during the last quarter. Commerce Bank lifted its position in Alnylam Pharmaceuticals by 1.7% in the fourth quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock worth $896,000 after buying an additional 77 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in Alnylam Pharmaceuticals by 7.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 89 shares during the last quarter. Finally, Oppenheimer & Co. Inc. lifted its position in Alnylam Pharmaceuticals by 2.1% in the third quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company’s stock worth $800,000 after buying an additional 93 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.